Janssen COVID-19 vaccine
COVID-19 vaccine of Johnson & Johnson
The Janssen COVID‑19 vaccine, (Ad26.COV2.S) sold under the brand name Jcovden, is a COVID‑19 vaccine that was developed by Janssen Vaccines in Leiden, Netherlands, and its Belgian parent company Janssen Pharmaceuticals, a subsidiary of American company Johnson & Johnson.
It is a viral vector vaccine based on a human adenovirus that has been modified to contain the gene for making the spike protein of the SARS-CoV-2 virus that causes COVID‑19. The body's immune system responds to this spike protein to produce antibodies. The vaccine requires only one dose and does not need to be stored frozen.
Clinical trials for the vaccine were started in June 2020, with phase III involving around 43,000 people. In January 2021, Janssen announced that 28 days after a completed vaccination, the vaccine was 66% effective in a one-dose regimen in preventing symptomatic COVID‑19, with an 85% efficacy in preventing severe COVID‑19 and 100% efficacy in preventing hospitalization or death caused by the disease.
The vaccine has been granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) and a conditional marketing authorization by the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency. In June 2023, the FDA revoked the emergency use authorization for the Janssen COVID-19 vaccine at the request of its manufacturer.
Because cases of thrombosis with thrombocytopenia syndrome and Guillain-Barré syndrome have been reported after receipt of the Janssen COVID‑19 vaccine, the US Centers for Disease Control and Prevention (CDC) recommends "preferential use of mRNA COVID‑19 vaccines over the Janssen COVID‑19 vaccine, including both primary and booster doses administered to prevent COVID‑19, for all persons aged 18 years of age and older. The Janssen COVID‑19 vaccine may be considered in some situations, including for persons with a contraindication to receipt of mRNA COVID‑19 vaccines." In February 2022, Johnson & Johnson announced it has temporarily suspended production of the vaccine though they also noted that it will likely resume at some point in the future and that it will honor all pre-existing contracts that oblige Janssen to supply its vaccine by using the millions of already existing vaccine doses in its inventory where requested.
Begin with the source’s own compact description: “Janssen COVID-19 vaccine” is cOVID-19 vaccine of Johnson & Johnson. The dossier treats that line as a proposition to test through Janssen, COVID-19 and vaccine, not as a finished interpretation.
Why this record matters
The phrase “cOVID-19 vaccine of Johnson & Johnson” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Aug 27, 2026. The linked authority identifier is Q98655215. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2020, 2021, 2023 and 2022.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Janssen COVID-19 vaccine”, its source revision and the description used here.
- Expand the search: follow Janssen COVID-19 vaccine primary sources, Janssen COVID-19 vaccine archive and Janssen research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Janssen COVID-19 vaccine”?
- What terminology or title could unlock a more precise catalogue search?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “Janssen COVID-19 vaccine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.